Supriya Lifescience Limited announces a significant milestone in its global operations with the successful attainment of the Good Manufacturing Practice (GMP) certification from Brazil’s Regulatory Authority, ANVISA, for its manufacturing facility located in Lote Parshuram, Ratnagiri District, Maharashtra, India.

The recent clearance obtained from this comprehensive audit showcases Supriya’s commitment to excellence but also signifies the successful registration of 8 Active Pharmaceutical Ingredients (APIs) with CADIFA. This milestone is poised to expedite and streamline the registration process for the company’s remaining APIs, facilitating a smoother pathway for their introduction into the Brazilian market.

Under the astute leadership of Chairman and Managing Director, Dr. Satish Wagh, Supriya Lifescience Limited's Lote Factory underwent a rigorous inspection by ANVISA, emerging with an exemplary record of "Zero" Observations in compliance. This accomplishment underscores the company's unwavering commitment to upholding the highest quality standards and employing advanced production and manufacturing techniques.

Dr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd stated, “It is a privilege for us to have obtained the GMP accreditation from ANVISA, which clearly demonstrates our strength of manufacturing capabilities from the state-of-the-art world class facility at Lote Parshuram, Ratnagiri District, in Maharashtra. This achievement truly speaks to our team's unwavering determination in adhering to rigorous standards for quality assurance, production processes, and overall adherence. Moreover, this certification not only enhances our presence in the Brazilian market but also strengthens our reputation as a trustworthy and quality-oriented pharmaceutical company and will increase our presence in the South American market.”

The success of Supriya Lifescience Ltd. in achieving Brazil's strict GMP standards positions the company for significant growth and has a potential of approximately Rs 200 crore in Brazilian market. The approval by ANVISA, demonstrates Supriya's persistent commitment to pharmaceutical quality control, data integrity, and GMP compliance in its manufacturing operations.